• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Promising phase 2 results for new plaque psoriasis therapy

byTomi JunandXu Gao
July 9, 2015
in Chronic Disease, Dermatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Guselkumab, an anti-interleukin-23 antibody, produced better responses in patients with moderate to severe plaque psoriasis than standard anti-TNF alpha therapy. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: Interleukin-23 promotes inflammation and is expressed at high levels in psoriasis. Guselkumab is a monoclonal antibody which targets interleukin-23 and inhibits its effects. This phase 2 trial compared various doses of guselkumab to placebo and adalimumab, an anti-TNF alpha antibody that is currently used to treat psoriasis.

The results showed that at a dose of 50-mg or higher every 3 months or so, guselkumab produced a significant response in about 80-85% of patients whereas standard therapy only produced a response in about 60% of patients. There were a similar number of adverse events between the different treatments and higher doses of guselkumab were not associated with more side effects. Longer studies would be needed to evaluate the complete safety profile of guselkumab.

This study sheds light on the importance of interleukin-23 in the pathogenesis of psoriasis. Another antibody, ustekinumab, inhibits both interleukin-12 and interleukin-23 and has been shown to be effective in psoriasis. The efficacy of guselkumab suggests that interleukin-23 may be more important than interleukin-12 in psoriasis.

Click to read the study, published today in NEJM 

Relevant Reading: Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

RELATED REPORTS

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

#VisualAbstract: Both dermatologists and patients with psoriatic disease expressed positive perspectives on strategies to improve cardiovascular disease prevention

#VisualAbstract Psoriasis is associated with an increase in incident venous thromboembolism and peripheral vascular disease

In-Depth [randomized controlled trial]: This phase 2 study involved about 300 patients with psoriasis involving at least 10% of the body and judged to be at least 3 out of 5 on the Physician’s Global Assessment (PGA) and at least 12 out of 72 on the Psoriasis Area and Severity Index. Patients were followed for 52 weeks. The primary endpoint was the proportion of patients with cleared or minimal psoriasis at week 16. The primary endpoint was reached in 7% of patients on placebo, 59% of patients on adalimumab and 79-86% of patients on doses of guselkumab of 50, 100 or 200mg. Response rates were lower in patients receiving either 5 or 15mg of guselkumab. The proportion of patients whose psoriasis cleared completely was 30% in the adalimumab group and 45% in patients receiving 100mg of guselkumab.

The rate of patients discontinuing treatment due to adverse events was low and similar across the placebo, guselkumab and adalimumab groups. Infections were the most common adverse event throughout the study period, in both antibody groups. Of note, three patients in the guselkumab group had cardiovascular events, including one death from a myocardial infarction.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: GuselkumabpsoriasisTNF
Previous Post

Cystic fibrosis gene therapy associated with stabilization of lung function

Next Post

COPD patients show substantial variation in lifetime rate of decline

RelatedReports

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis
StudyGraphics

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

April 7, 2022
#VisualAbstract: Both dermatologists and patients with psoriatic disease expressed positive perspectives on strategies to improve cardiovascular disease prevention
StudyGraphics

#VisualAbstract: Both dermatologists and patients with psoriatic disease expressed positive perspectives on strategies to improve cardiovascular disease prevention

January 28, 2022
#VisualAbstract Psoriasis is associated with an increase in incident venous thromboembolism and peripheral vascular disease
StudyGraphics

#VisualAbstract Psoriasis is associated with an increase in incident venous thromboembolism and peripheral vascular disease

December 16, 2021
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Treatment of immune-mediated inflammatory diseases with tumor necrosis factor inhibitors is associated with lower COVID-19 hospitalization and death rates compared to other treatments

October 20, 2021
Next Post
Dual PDE3/PDE4 inhibitor may be effective treatment for asthma and COPD

COPD patients show substantial variation in lifetime rate of decline

Adverse pregnancy outcomes associated with thrombophilias [Classics Series]

Adverse pregnancy outcomes associated with thrombophilias [Classics Series]

Oral cholera vaccine effective for outbreak control

Oral cholera vaccine moderately effective in reducing the burden of severely dehydrating diarrhea

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir
  • Oral methylprednisolone may reduce risk of progressive renal failure in patients with IgA nephropathy: TESTING Trial
  • #VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.